HU9902296D0 - Pharmaceutical composition for treating caltification - Google Patents

Pharmaceutical composition for treating caltification

Info

Publication number
HU9902296D0
HU9902296D0 HU9902296A HUP9902296A HU9902296D0 HU 9902296 D0 HU9902296 D0 HU 9902296D0 HU 9902296 A HU9902296 A HU 9902296A HU P9902296 A HUP9902296 A HU P9902296A HU 9902296 D0 HU9902296 D0 HU 9902296D0
Authority
HU
Hungary
Prior art keywords
caltification
treating
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
HU9902296A
Other languages
English (en)
Inventor
Zoltan Dardai
Original Assignee
Dardai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dardai filed Critical Dardai
Priority to HU9902296A priority Critical patent/HU9902296D0/hu
Publication of HU9902296D0 publication Critical patent/HU9902296D0/hu
Priority to PCT/HU2000/000053 priority patent/WO2001003774A2/en
Priority to AU54165/00A priority patent/AU5416500A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9902296A 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification HU9902296D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU9902296A HU9902296D0 (en) 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification
PCT/HU2000/000053 WO2001003774A2 (en) 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification
AU54165/00A AU5416500A (en) 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9902296A HU9902296D0 (en) 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification

Publications (1)

Publication Number Publication Date
HU9902296D0 true HU9902296D0 (en) 1999-10-28

Family

ID=89998669

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902296A HU9902296D0 (en) 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification

Country Status (3)

Country Link
AU (1) AU5416500A (hu)
HU (1) HU9902296D0 (hu)
WO (1) WO2001003774A2 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227496B1 (en) * 2001-11-16 2011-07-28 Zoltan Dardai Transdermal pharmaceutical composition containing aspirine for the treatment of sclerosis
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE596326A (fr) * 1959-11-02 1961-02-15 Guy Leopold Van Moorleghem Soluté injectable d'aspirine et sou procédé de préparation
BE637999A (hu) * 1962-10-10
FR2295753A1 (fr) * 1974-12-23 1976-07-23 Despin Jean Composition a base d'acide acetyl-salicylique a usage topique
FR2297612A1 (fr) * 1975-01-20 1976-08-13 Moorleghem Guy Van Procede de fabrication d'un produit analgesique a usage externe
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
JPS53124607A (en) * 1977-04-06 1978-10-31 Fujimoto Seiyaku Kk Novel preparation of aspirin included in dextrine analogue
FR2556218B1 (fr) * 1983-12-12 1986-11-14 Gerard Alain Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS6416726A (en) * 1987-07-08 1989-01-20 Teisan Seiyaku Kk Production of aspirin dl-lysine injection
FR2648711B1 (fr) * 1989-05-17 1991-10-11 Jean Blum Complexe soluble dans l'eau et stabilise de l'acide acetyl-salicylique et son procede de fabrication
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
WO2000002565A1 (en) * 1998-07-09 2000-01-20 Alexander Galat Injectable sodium acetylsalicylate composition and method

Also Published As

Publication number Publication date
WO2001003774A2 (en) 2001-01-18
AU5416500A (en) 2001-01-30
WO2001003774A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
PL351387A1 (en) Pharmaceutical composition
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
PT1466615E (pt) Composição farmacêutica
GB9923436D0 (en) Pharmaceutical compositions
PL350167A1 (en) Medicament for treating hypertension
PL343769A1 (en) Pharmaceutical composition
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
GB9818591D0 (en) Pharmaceutical composition
IL145632A0 (en) Pharmaceutical compounds
GB9904163D0 (en) Pharmaceutical compositions
GB9916434D0 (en) Pharmaceutical compounds
GB9911017D0 (en) Pharmaceutical compositions
GB9914255D0 (en) Pharmaceutical compounds
EP1124557A4 (en) PHARMACEUTICAL COMPOSITION
GB9903784D0 (en) Pharmaceutical compounds
HUP0202652A3 (en) Pharmaceutical carrier composition
GB9904911D0 (en) Pharmaceutical compositions
EP1203582A4 (en) MEDICINAL COMPOSITIONS FOR THE TREATMENT OF LOWER UROPATHY
HU9902296D0 (en) Pharmaceutical composition for treating caltification
GB2373499B (en) Pharmaceutical compounds
HU0001889D0 (en) Pharmaceutical composition for treating migraine
GB9902651D0 (en) Pharmaceutical compositions
HRPK20020201B1 (en) Pharmaceutical compositions for treating psoriasis